Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

omparator therapies assigned by the G-BA under Germany's AMNOG law.  The determination reflected the absence of a comparator under AMNOG law specifically for this stage of aggressive NHL because prior to the approval of PIXUVRI in the European Union (E.U.), there was no therapy specifically approved for this stage of disease. The G-BA also decided that the prescribability for PIXUVRI should be limited to hematologists and oncologists. CTI is currently negotiating pricing with the GKV-SV, the Federal Association of Statutory Health Insurance Funds.

Research and Development:  New Data Presentation on Pacritinib's Safety Profile

  • Reported results from pooled integrated safety analysis from four Phase 1 and 2 clinical studies that demonstrated the safety, tolerability and persistence of pacritinib, CTI's novel, oral JAK2/FLT3 inhibitor, in patients with myelofibrosis at the European Hematology Association Congress.
  • Reported on the publication of a comprehensive article summarizing preclinical and clinical data for pacritinib, authored by Srdan Verstovsek, M.D., Ph.D., et al., in the journal Drugs of the Future 2013.
  • Corporate:  Added to Russell Indices and Established Leadership for SAB

  • Added to Russell Investments' Russell 3000® and Russell Global indices.
  • Named distinguished cancer investigator, Daniel Von Hoff, M.D., F.A.C.P., as Chairman and to lead formation of CTI's Scientific Advisory Board (SAB).
  • Second Quarter 2013 Financial ResultsTotal revenues for the second quarter and the six months ended June 30, 2013 were $0.3 million and $1.4 million, respectively.  The revenues were solely attributable to net product sales of PIXUVRI.  CTI sells PIXUVRI directly to health care providers and through a limited number of wholesale distributors in the E.U.  CTI records product sales upon receipt of the product by the health care provider or distributor, n
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
    3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
    7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
    9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
    10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
    (Date:11/22/2014)... Nov. 21, 2014  Particle Sciences, Inc (PSI), ... developed and manufactured a new innovative vaginal ring ... and Development arm of Exeltis Pharmaceuticals.  According to ... Management at Particle Sciences, "This vaginal ring was ... material sciences and modeling expertise.  We are thrilled ...
    (Date:11/21/2014)... , Nov. 21, 2014  The University of ... host the ceremonial groundbreaking of the new A. James ... The new building will cultivate transformative new engineering and ... Taking place at 10:00 a.m. on November 21 ... Paint Branch Parking Lot, adjacent to the Jeong H. ...
    Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
    ... MARLTON, N.J. , July 29 Free For All® ... Choice, Inc. today announced a plan to offer MMM/PMC members access to ... use of RxCut®Plus cards. , , ... The RxCut®Plus card works much like a traditional discount coupon that entitles ...
    ... , July 29 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... quarter ended June 30, 2010 financial results on Thursday, August ... a live webcast and conference call at 5:00 p.m. Eastern time . ... Orexigen management will host the ...
    Cached Medicine Technology:Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount 2Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount 3Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount 4Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010 2
    (Date:11/23/2014)... Beach, CA (PRWEB) November 23, 2014 ... of American Medical Aesthetics & Wellness was recently ... Asher Milgrom, Ph.D. is president and CEO of American ... Dr. Asher Milgrom received a full scholarship to ... and the Medical School at the University of Chicago, ...
    (Date:11/23/2014)... 23, 2014 BambooFlooringChina.com , the world’s ... click strand woven bamboo flooring collection. Now, the business ... the company’s CEO, the promotion is valid until Dec. 20, ... with a smooth and dust-free surface, which makes it very ... the industry, the company wants to make its website the ...
    (Date:11/22/2014)... November 23, 2014 PrettyTailor , ... with a new big promotion. Customers can buy new ... information, customers can visit its website. , As a ... and occasion dresses. It mainly provides four types of ... dresses and flower girl dresses. It also provides a ...
    (Date:11/22/2014)... November 23, 2014 Today, Dylan Queen, ... new collection of wedding dresses; the business offers a ... related accessories for ladies worldwide, allowing them to create ... of the company, this new collection of chic wedding ... Moreover, they are offered at discounted rates now. Dylan ...
    (Date:11/22/2014)... (PRWEB) November 22, 2014 Nocturia ... as the complaint that the individual has to ... voiding. The report “Nocturia – Pipeline Review, H2 ... for Nocturia, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
    Breaking Medicine News(10 mins):Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
    ... Today,s McCain Myth: John McCain would stand up ... The following release,was issued today by the Democratic ... John McCain says he will stand up ... the heart of American innovation, growth and,prosperity." But ...
    ... all pregnant women experience morning sickness - ... MorningSicknessHelp.com, "I was really sick in the beginning, and I thought, ,What the h--- have ... done?, - Marcia Cross, Morning ... 10 Oh Mama!, creator of the first,nutrition bar with DHA and engineered to meet ...
    ... Meaningful Measurement of Performance, ... from HealthLeaders-InterStudy, NASHVILLE, Tenn., June 10 ... reports the New York,Health Plan Association, in cooperation ... a statewide pay-for-performance (P4P),program for primary care physicians. ...
    ... to be led by SAP veteran, WAYNE, Pa., ... ICW Labs, a Silicon Valley based R&D organization,focused on ... its eHealth,solutions. ICW Labs will be headed by Thomas ... http://www.newscom.com/cgi-bin/prnh/20071126/NEM090LOGO ), The new ICW Lab is ...
    ... neuroscientists at UQ have discovered a new way to reduce ... disease. , Memory loss in people with Alzheimer,s disease ... a build-up of the neuro-toxin Amyloid beta the major ... and corresponding degeneration of a specific population of nerve cells ...
    ... helps them use online programs as well as drugs ... -- Insomnia among U.S. combat veterans returning from Iraq ... chronic insomnia, according to University of Pittsburgh researchers. , ... 14 insomnia patients and 14 good sleepers, and found ...
    Cached Medicine News:Health News:Democratic National Committee McCain Myth Buster: John McCain and America's Small Businesses 2Health News:Democratic National Committee McCain Myth Buster: John McCain and America's Small Businesses 3Health News:Oh Mama! Heads Back to the Lab to Create the First Ever Ginger-Ale for Moms-To-Be 2Health News:Statewide Pay-For-Performance Program in Store for New York Physicians 2Health News:InterComponentWare Establishes ICW Labs 2Health News:QBI neuroscientists make Alzheimer's disease advance 2Health News:Combat Vets Display Severe Sleep Disorders 2
    ... Flextend lead is a ... with an extendable/retractable active-fixation ... design offers various lead ... implantation in the atrium ...
    ... KY is a low profile implantable ... for stimulation of either the atrium ... is supplied with a screwdriver shape ... the lead. The ring tip and ...
    ... profile endocardial permanent pacing leads with an ... size of only 4.8 F and a ... Physique lead is the smallest extendable/retractable bipolar ... straight and pre-formed J configurations, Physique leads ...
    Used to occupy an empty hole which is not being used in an implantablepacemaker header....
    Medicine Products: